Literature DB >> 1516073

Baclofen in the treatment of dystonia.

P Greene1.   

Abstract

Dystonia refers to involuntary, prolonged muscle contractions leading to sustained, often twisting, postures. High dose anticholinergic therapy for childhood onset dystonia, botulinum toxin injections for focal dystonia, and levodopa for diurnal dystonia provide symptomatic relief for some patients. Despite this, treatment of both idiopathic and secondary dystonia remains inadequate for many patients. Baclofen, a pre-synaptic acting GABA agonist, has been reported to benefit dystonia in a number of retrospective studies. Dramatic improvement in symptoms, especially in gait, was found in almost 30% of 31 children and adolescents with idiopathic dystonia in one retrospective study using doses ranging from 40 to 180 mg daily. The response to baclofen of adults with focal dystonia is less dramatic. One series of 60 adults with cranial dystonia found sustained benefit in 18%. Smaller series have not consistently found significant benefit in adults. Baclofen has been used to treat several secondary dystonias: tardive dystonia has occasionally been reported to improve and there are isolated reports of improvement in dystonia occurring in Parkinson's disease and in glutaric aciduria.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516073     DOI: 10.1097/00002826-199208000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

Review 1.  Meige syndrome: what's in a name?

Authors:  Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2009-05-19       Impact factor: 4.891

Review 2.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 3.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

4.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

Review 5.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

6.  Olfactory Hallucinations without Clinical Motor Activity: A Comparison of Unirhinal with Birhinal Phantosmia.

Authors:  Robert I Henkin; Samuel J Potolicchio; Lucien M Levy
Journal:  Brain Sci       Date:  2013-11-15

7.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

8.  Tardive Dystonia.

Authors:  Frank Skidmore; Stephen G Reich
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

Review 9.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

10.  Torsion Dystonia in Children.

Authors:  Vanessa K. Hinson; Christopher G. Goetz
Journal:  Curr Treat Options Neurol       Date:  2003-07       Impact factor: 3.972

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.